Abbvie 3Q Revenues: $12.9 billion (+52%) 3Q Earnings: $2.3 billion (+23%) YTD Revenues: $31.9 billion (+30%) YTD Earnings: $4.6 billion (-10%) Comments: Revenues from the Immunology Portfolio were $5.8 billion, an increase of 15%. Global Humira revenues were $5.1 billion, up 4%. U.S. Humira revenues were $4.2 billion, up 8%. Internationally, Humira sales were down 9% to $951 million due to biosimilar competition. Global Skyrizi sales were $435 million and Global Rinvoq sales ...